Trial Profile

A clinical study of BC-007

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BC-007-Dragonboat Biopharmaceutical (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

30 Jun 2022 New trial record
25 Jun 2022 According to Sanyou Biopharmaceuticals media release, the Dragon Boat Biopharmaceutical announced that its IND application of BC007 was officially accepted by National Medical Products Administration (NMPA) under the acceptance number CXSL2200267. This drug is intended for the treatment of late stage solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com